6.99

0.71% -0.05

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $6.99, with a volume of 3.14M. It is down -0.71% in the last 24 hours and up +29.44% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Previous Close:

$7.04

Open:

$7.005

24h Volume:

3.14M

Relative Volume:

1.28

Market Cap:

$855.35M

Revenue:

Net Income/Loss:

$-258.08M

P/E Ratio:

-2.5418

EPS:

-2.75

Net Cash Flow:

$-202.32M

1W Performance:

-12.73%

1M Performance:

+29.44%

6M Performance:

-59.94%

1Y Performance:

-70.04%

1-Day Range:

$6.85

$7.30

1-Week Range:

$6.21

$8.19

52-Week Range:

$4.55

$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

299

Twitter

@rocketpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

RCKT's Discussions on Twitter

Compare RCKT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCKT Rocket Pharmaceuticals Inc	6.99	855.35M	0	-258.08M	-202.32M	-2.75
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Dec-30-24	Initiated	Wedbush	Outperform
Dec-18-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

05:28 AM

Chardan Capital Lowers Price Target for RCKT to $45, Maintains B - GuruFocus

05:28 AM

03:32 AM

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa - GuruFocus

03:32 AM

May 09, 2025

Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News - GuruFocus

May 09, 2025

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American S - GuruFocus

May 09, 2025

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Business Wire

May 09, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News - GuruFocus

May 09, 2025

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research

May 09, 2025

Rocket Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 09, 2025

JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

May 09, 2025

Mariner LLC Takes $139,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 09, 2025

May 08, 2025

Rocket Pharmaceuticals: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress - BioSpace

May 08, 2025

Rocket Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

May 07, 2025

Post-Trade Analysis: Rocket Pharmaceuticals Inc (RCKT) Slides -19.62, Closing at 6.31 - DWinneX

May 07, 2025

Citizen Health Partner to Support Drug Development and Long-Term Patient Outcomes in PKP2 Cardiomyopathy - Morningstar

May 07, 2025

May 06, 2025

Envestnet Asset Management Inc. Purchases 1,280 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 06, 2025

May 05, 2025

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Stock: A Value Hunter’s Investment? - Stocksregister

May 05, 2025

Wells Fargo & Company MN Buys 10,147 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 05, 2025

May 03, 2025

Trading (RCKT) With Integrated Risk Controls - news.stocktradersdaily.com

May 03, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

May 03, 2025

Rocket Pharmaceuticals (RCKT) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025

May 02, 2025